Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Relay Therapeutics Inc (NASDAQ: RLAY) closed at $3.88 in the last session, down -1.02% from day before closing price of $3.92. In other words, the price has decreased by -$1.02 from its previous closing price. On the day, 1.51 million shares were traded.
Ratios:
We take a closer look at RLAY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 18.42 and its Current Ratio is at 18.42. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 10, 2024, Upgraded its rating to Buy and sets its target price to $16 from $10.60 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 11 ’25 when Patel Sanjiv sold 140,182 shares for $3.85 per share. The transaction valued at 539,701 led to the insider holds 625,948 shares of the business.
Patel Sanjiv sold 75,324 shares of RLAY for $278,699 on Feb 13 ’25. The President and CEO now owns 883,089 shares after completing the transaction at $3.70 per share. On Jan 29 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 26,541 shares for $4.55 each. As a result, the insider received 120,762 and left with 419,681 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 64.88 while its Price-to-Book (P/B) ratio in mrq is 0.77.
Stock Price History:
Over the past 52 weeks, RLAY has reached a high of $11.02, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is -11.68%, while the 200-Day Moving Average is calculated to be -37.13%.
Shares Statistics:
A total of 166.89M shares are outstanding, with a floating share count of 125.56M. Insiders hold about 24.99% of the company’s shares, while institutions hold 76.24% stake in the company.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Relay Therapeutics Inc (RLAY) in the stock market.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.55 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$2.32 and -$2.62 for the fiscal current year, implying an average EPS of -$2.47. EPS for the following year is -$2.54, with 9.0 analysts recommending between -$2.23 and -$3.32.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $60M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $15.08M. In the same quarter a year ago, actual revenue was $25.55M
